McKesson Corporation $MCK Shares Sold by Erste Asset Management GmbH

Erste Asset Management GmbH lessened its stake in shares of McKesson Corporation (NYSE:MCK) by 60.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 3,359 shares of the company’s stock after selling 5,237 shares during the period. Erste Asset Management GmbH’s holdings in McKesson were worth $2,559,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of MCK. Norges Bank purchased a new position in shares of McKesson in the second quarter worth approximately $1,346,661,000. Alliancebernstein L.P. boosted its position in McKesson by 150.4% during the 2nd quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock worth $1,661,956,000 after acquiring an additional 1,362,386 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in McKesson by 56.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock valued at $906,109,000 after acquiring an additional 446,060 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of McKesson by 45.6% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock valued at $610,977,000 after purchasing an additional 261,296 shares during the period. Finally, Acadian Asset Management LLC lifted its position in shares of McKesson by 68.0% in the second quarter. Acadian Asset Management LLC now owns 636,596 shares of the company’s stock worth $466,441,000 after purchasing an additional 257,670 shares in the last quarter. 85.07% of the stock is owned by institutional investors.

McKesson Stock Performance

NYSE MCK opened at $984.61 on Friday. McKesson Corporation has a twelve month low of $621.88 and a twelve month high of $987.37. The stock has a market cap of $120.60 billion, a PE ratio of 28.32, a PEG ratio of 1.59 and a beta of 0.40. The firm has a 50-day simple moving average of $868.77 and a 200 day simple moving average of $806.54.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.19 by $0.15. The firm had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Research analysts forecast that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, March 2nd. McKesson’s dividend payout ratio is presently 9.43%.

Insiders Place Their Bets

In other news, EVP Leann B. Smith sold 190 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total transaction of $179,550.00. Following the completion of the sale, the executive vice president owned 2,989 shares in the company, valued at $2,824,605. The trade was a 5.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Maria Martinez sold 349 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $939.87, for a total value of $328,014.63. Following the completion of the transaction, the director owned 301 shares in the company, valued at approximately $282,900.87. This represents a 53.69% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 1,143 shares of company stock valued at $1,046,070. 0.08% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

MCK has been the subject of a number of research reports. Weiss Ratings cut McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research report on Thursday, February 5th. Barclays lifted their price target on McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. JPMorgan Chase & Co. increased their price objective on McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Wells Fargo & Company raised their price objective on shares of McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a research report on Thursday, February 5th. Finally, Mizuho boosted their target price on shares of McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a research report on Thursday, February 5th. Thirteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, McKesson currently has a consensus rating of “Moderate Buy” and a consensus price target of $943.50.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.